img

News Topical, Digital Desk : Dr Reddy's Laboratories informed after the stock market closed on Friday that the USFDA (US Food and Drug Administration) has issued 7 objections after inspection of the manufacturing facility located in Srikakulam district of Andhra Pradesh. This inspection lasted from July 10 to July 18, 2025. The company will now have to respond to these objections, on the basis of which the further regulatory process will be decided. When an Indian pharmaceutical company wants to export medicines to the US, the USFDA inspects its manufacturing facilities. This is called USFDA inspection.

The company said in an exchange filing that USFDA has today completed GMP (Good Manufacturing Practice) and Pre-Approval Inspection (PAI) at our formulation manufacturing facility FTO 11, Srikakulam, Andhra Pradesh, India. This inspection was conducted between July 10 and July 18, 2025. After this inspection, USFDA has issued 7 objections under Form 483, which we will address within the stipulated time frame. Share performance The company's stock closed 0.38 per cent down at Rs 1,258.30 on Friday. The company's stock has seen a decline of 5.64 per cent in the last one year. 


Read More: Multibagger: As soon as the market opened, buyers pounced on the stock, an upper circuit was applied, what happened

--Advertisement--

Dr Reddy’s Laboratories USFDA Inspection Form 483 Srikakulam facility GMP inspection PAI inspection 7 observations USFDA notice pharmaceutical compliance Andhra Pradesh plant Dr. Reddy’s USFDA update drug manufacturing audit regulatory inspection